PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment
Carina Biotech files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is directed at a first-in-human Phase 1/2a clinical trial in advanced
Story by Hayden Smith, featured in The Weekend Australian, 5 June 2021 Battling blood cancer in my 20s, I put my faith in a clinical trial for a promising new
Off-the-shelf CAR-T therapy clinical trials to start in Australia next year CANCER patients would have access to off-the-shelf immunotherapies to reprogram their immune system to fight tumours at a fraction
Seattle cancer trial ‘very good news’ for young patients More than 90 percent of children and young adults with acute lymphoblastic leukemia, or ALL, are in remission after treatment as
